79179556 - HUMABODY

Information

• Trademark
• 79179556

• Source

• Serial Number

  79179556

• Registration Number

  5158366

• International Classifications

  • 1 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry
  • 5 - Pharmaceutical and veterinary preparations
  • 40 - Treatment of materials
  • 42 - Scientific and technological services and research and design relating thereto

• Filing Date

  December 17, 2014
  10 years ago

• Registration Date

  March 14, 2017
  7 years ago

• Transaction Date

  December 12, 2024
  28 days ago

• Status Date

  June 27, 2024
  6 months ago

• Published for Opposition Date

  September 20, 2016
  8 years ago

• Location Date

  June 27, 2024
  6 months ago

• Status Code

  707

• Current Location

  Historical data usage

  Employee Name

  POLLACK, ALISON

• Attorney Docket Number

  31229-422717

  Attorney Name

  Rebecca Liebowitz

• Owners

  • CRESCENDO BIOLOGICS LTD

Case File Statements

• GS0401: [ Treatment and transformation of materials for others, namely, the manufacture of chemicals, biologicals, antibodies and antibody fragments; contract manufacturing services in the field of chemicals, biologicals, antibodies and antibody fragments; custom manufacture of therapies using antibodies and antibody fragments ]
• GS0051: pharmaceutical preparations for the treatment of cancer [ , autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases ] ; veterinary preparations for the treatment of cancer [ , autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases ] ; therapeutic pharmaceutical preparations in the nature of antibodies and antibody fragments for medical and veterinary purposes; antibodies being pharmaceutical preparations for the treatment of cancer [ , autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases ] ; antibody fragments being pharmaceutical preparations for the treatment of cancer [ , autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases] ; antibody therapeutics in the nature of therapeutic agents for the treatment of cancer [ , autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases ] ; medical diagnostic reagents and veterinary diagnostic reagents in the nature of antibodies and antibody fragments; antibodies and antibody fragments being therapeutic pharmaceuticals for the treatment of cancer [ , autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases ] and or use in the manufacture of therapeutic products
• GS0011: chemicals used in industry and science; [ chemical test kits for in vitro testing for laboratory research purposes; ] biochemicals, namely, monoclonal antibodies and antibody fragments all being proteins for in vitro scientific and laboratory research use; biochemicals, namely, monoclonal antibodies and antibody fragments for in vitro scientific and laboratory research use; antibodies and antibody fragments all being protein in raw material form for scientific research purposes; antibody reagents used for the detection of antigens in cell and tissue analysis for scientific and laboratory in vitro diagnostic use; antibodies and antibody fragments all being proteins for industrial use in the discovery, preclinical and clinical development of therapeutic products
• GS0421: [ Scientific and technological services, namely, scientific research, analysis and testing and research and design in the field of chemicals, biologicals, antibodies and antibody fragments; Scientific laboratory services in the field of antibodies and antibody fragments; research in the field of the development of antibodies and antibody fragments; provision of scientific information in the field of antibodies and antibody fragments for medical and veterinary purposes; engineering of antibodies and antibody fragments; scientific services, namely, drug discovery, preclinical and clinical development of therapeutic products; consultancy services relating thereto, namely, consulting in the field of antibody and antibody fragment design ]

Case File Event Statements

• 1/3/2016 - 9 years ago

  1 - SN ASSIGNED FOR SECT 66A APPL FROM IB Type: REPR

• 1/4/2016 - 9 years ago

  2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS

• 1/4/2016 - 9 years ago

  3 - ASSIGNED TO EXAMINER Type: DOCK

• 1/5/2016 - 9 years ago

  4 - NON-FINAL ACTION WRITTEN Type: CNRT

• 1/6/2016 - 9 years ago

  5 - NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Type: RFCR

• 1/8/2016 - 9 years ago

  6 - APPLICATION FILING RECEIPT MAILED Type: MAFR

• 1/11/2016 - 9 years ago

  7 - REFUSAL PROCESSED BY MPU Type: RFRR

• 1/11/2016 - 9 years ago

  8 - NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Type: RFCS

• 2/1/2016 - 8 years ago

  9 - REFUSAL PROCESSED BY IB Type: RFNT

• 7/11/2016 - 8 years ago

  11 - TEAS CHANGE OF CORRESPONDENCE RECEIVED Type: TCCA

• 7/11/2016 - 8 years ago

  10 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA

• 7/15/2016 - 8 years ago

  12 - ASSIGNED TO LIE Type: ALIE

• 7/15/2016 - 8 years ago

  13 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 7/15/2016 - 8 years ago

  14 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 7/29/2016 - 8 years ago

  15 - FINAL REFUSAL WRITTEN Type: CNFR

• 7/29/2016 - 8 years ago

  16 - FINAL REFUSAL E-MAILED Type: GNFR

• 7/29/2016 - 8 years ago

  17 - NOTIFICATION OF FINAL REFUSAL EMAILED Type: GNFN

• 8/8/2016 - 8 years ago

  18 - TEAS REQUEST FOR RECONSIDERATION RECEIVED Type: ERFR

• 8/8/2016 - 8 years ago

  19 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 8/8/2016 - 8 years ago

  20 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 8/9/2016 - 8 years ago

  21 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA

• 8/9/2016 - 8 years ago

  22 - EXAMINERS AMENDMENT E-MAILED Type: GNEA

• 8/9/2016 - 8 years ago

  23 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN

• 8/9/2016 - 8 years ago

  24 - EXAMINER'S AMENDMENT ENTERED Type: XAEC

• 8/9/2016 - 8 years ago

  25 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA

• 8/17/2016 - 8 years ago

  26 - LAW OFFICE PUBLICATION REVIEW COMPLETED Type: PREV

• 8/31/2016 - 8 years ago

  27 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP

• 8/31/2016 - 8 years ago

  28 - NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB Type: OP2R

• 8/31/2016 - 8 years ago

  29 - NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Type: OPNS

• 9/20/2016 - 8 years ago

  30 - PUBLISHED FOR OPPOSITION Type: PUBO

• 9/20/2016 - 8 years ago

  31 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB

• 10/18/2016 - 8 years ago

  32 - EXTENSION OF TIME TO OPPOSE RECEIVED Type: ETOF

• 11/18/2016 - 8 years ago

  33 - NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB Type: OPNX

• 2/3/2017 - 7 years ago

  34 - EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED Type: ETOP

• 3/14/2017 - 7 years ago

  35 - REGISTERED-PRINCIPAL REGISTER Type: R.PR

• 6/14/2017 - 7 years ago

  36 - FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Type: FICR

• 6/22/2017 - 7 years ago

  37 - FINAL DISPOSITION PROCESSED Type: FIMP

• 6/22/2017 - 7 years ago

  38 - FINAL DISPOSITION NOTICE SENT TO IB Type: FICS

• 7/14/2017 - 7 years ago

  39 - FINAL DECISION TRANSACTION PROCESSED BY IB Type: FINO

• 12/7/2017 - 7 years ago

  40 - NEW REPRESENTATIVE AT IB RECEIVED Type: NREP

• 3/14/2022 - 2 years ago

  41 - COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED Type: REM3

• 8/19/2023 - a year ago

  42 - RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED Type: RHRD

• 9/13/2023 - a year ago

  43 - TEAS SECTION 71 RECEIVED Type: ES71

• 10/27/2023 - a year ago

  44 - LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED Type: LIMN

• 5/7/2024 - 8 months ago

  45 - CASE ASSIGNED TO POST REGISTRATION PARALEGAL Type: APRE

• 6/27/2024 - 6 months ago

  46 - REGISTERED - PARTIAL SEC 71 ACCEPTED Type: 71.P

• 11/8/2024 - 2 months ago

  48 - RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED Type: RHRD

• 12/12/2024 - 28 days ago

  49 - INTERNATIONAL REGISTRATION RENEWED Type: RNWL

• 6/27/2024 - 6 months ago

  47 - NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED Type: NA71